Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-11 of 11

Sort by

Sort Order Select

Journal Articles

CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS

Blood (2024) 143 (3): 258–271.

https://doi.org/10.1182/blood.2022018905

Published: 2024

Includes: Supplemental data

Journal Articles

Affinity of Anti-CD19 Antibodies Determines Subsequent CART19 Activation, Apoptosis and CRS in Preclinical Models

Blood (2023) 142 (Supplement 1): 6796.

https://doi.org/10.1182/blood-2023-179408

Published: 2023

Journal Articles

Identification of IL-4 As a Key Regulator of CAR T-Cell Exhaustion Using Functional Genomics and Correlates of the Zuma-1 Clinical Trial

Carli M. Stewart, Michelle J. Cox, Reona Leo Sakemura, Ekene J. Ogbodo, Ismail Can, Claudia Manriquez-Roman, Kun Yun, Olivia Sirpilla, James H. Girsch, Truc Huynh, Elizabeth L. Siegler, Jenny J Kim, Mike Mattie, Nathalie Scholler, Simone Filosto, Saad S. Kenderian

Blood (2022) 140 (Supplement 1): 4536–4537.

https://doi.org/10.1182/blood-2022-160219

Published: 2022

Journal Articles

Immunosuppressive Monocyte Modulation of CAR T Cell Functions and Impact on Response to CART19

Kun Yun, Reona Leo Sakemura, Michelle J. Cox, Truc Huynh, Claudia Manriquez-Roman, Olivia Sirpilla, Carli M. Stewart, James H. Girsch, Ekene J. Ogbodo, Ismail Can, Brooke Kimball, Lionel A. Kankeu Fonkoua, Mehrdad Hefazi, Michael W. Ruff, Elizabeth L. Siegler, Mike Mattie, Sao-Mai Nguyen-Mau, Simone Filosto, Saad S. Kenderian

Blood (2022) 140 (Supplement 1): 10263–10264.

https://doi.org/10.1182/blood-2022-164706

Published: 2022

Journal Articles

Chimeric Antigen Receptor Engineering of Mesenchymal Stromal Cells (CAR-MSC) Enhance Immunosuppression and Outcomes in Graft Versus Host Disease (GvHD) Preclinical Models

Olivia Sirpilla, Reona Leo Sakemura, Mehrdad Hefazi, James H. Girsch, Truc Huynh, Michelle J. Cox, Kendall J. Schick, Claudia Manriquez-Roman, Ismail Can, Kun Yun, Carli M. Stewart, Ekene J. Ogbodo, Elizabeth L. Siegler, Saad S. Kenderian

Blood (2022) 140 (Supplement 1): 1579–1580.

https://doi.org/10.1182/blood-2022-158872

Published: 2022

Journal Articles

Differential Susceptibility to Senescence in CART Cells Based on Co-Stimulatory Signaling

Ismail Can, Reona Leo Sakemura, Claudia Manriquez-Roman, Olivia Sirpilla, Carli M. Stewart, Kun Yun, Michelle J. Cox, Truc Huynh, James H. Girsch, Ekene J. Ogbodo, Lionel A. Kankeu Fonkoua, Mehrdad Hefazi, Michael W. Ruff, Justin C. Boysen, Elizabeth L. Siegler, Atakan Ekiz, Saad S. Kenderian, Neil E. Kay

Blood (2022) 140 (Supplement 1): 8600–8601.

https://doi.org/10.1182/blood-2022-163446

Published: 2022

Journal Articles

CD19 Antigen Occupancy on Cancer Cells with the CD19 Monoclonal Antibody Tafasitamab Improves the Activation, Antitumor Efficacy, and Safety Profile of CART19 Cell Therapy

Blood (2022) 140 (Supplement 1): 2362–2364.

https://doi.org/10.1182/blood-2022-158273

Published: 2022

Journal Articles

Optimized Inhibition of GM-CSF in Preclinical Models of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy

Blood (2021) 138 (Supplement 1): 2777.

https://doi.org/10.1182/blood-2021-149859

Published: 2021

Journal Articles

Favorable Modulation of Chimeric Antigen Receptor T Cells Safety and Efficacy By the Non-Covalent BTK Inhibitor Vecabrutinib

Blood (2021) 138 (Supplement 1): 906.

https://doi.org/10.1182/blood-2021-151073

Published: 2021

Journal Articles

TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma

Blood (2021) 138 (Supplement 1): 901.

https://doi.org/10.1182/blood-2021-148591

Published: 2021

Journal Articles

The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models

Blood (2021) 138 (Supplement 1): 2412.

https://doi.org/10.1182/blood-2021-145649

Published: 2021

NARROW

CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS

Affinity of Anti-CD19 Antibodies Determines Subsequent CART19 Activation, Apoptosis and CRS in Preclinical Models

Identification of IL-4 As a Key Regulator of CAR T-Cell Exhaustion Using Functional Genomics and Correlates of the Zuma-1 Clinical Trial

Immunosuppressive Monocyte Modulation of CAR T Cell Functions and Impact on Response to CART19

Chimeric Antigen Receptor Engineering of Mesenchymal Stromal Cells (CAR-MSC) Enhance Immunosuppression and Outcomes in Graft Versus Host Disease (GvHD) Preclinical Models

Differential Susceptibility to Senescence in CART Cells Based on Co-Stimulatory Signaling

CD19 Antigen Occupancy on Cancer Cells with the CD19 Monoclonal Antibody Tafasitamab Improves the Activation, Antitumor Efficacy, and Safety Profile of CART19 Cell Therapy

Optimized Inhibition of GM-CSF in Preclinical Models of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy

Favorable Modulation of Chimeric Antigen Receptor T Cells Safety and Efficacy By the Non-Covalent BTK Inhibitor Vecabrutinib

TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma

The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only